Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Authors:
Open Access
- 7 November 2009
- journal article
- case report
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (4) , 307-310
Abstract
Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer. It exhibits a good safety profile, but is the cause of a number of dermatological adverse effects. The most common and often the most troublesome is a specific hand-foot skin reaction (HFSR) affecting at least 30% of patients. It occurs predominantly on hyperkeratotic areas of the hands and feet that are subject to chronic pressure, suggesting the role played by repeated subclinical traumas in its pathophysiological mechanism. We report here two new cases of sorafenib-induced HFSR, but associated with identical lesions occurring on specific areas of friction (scar, elbows) and suggestive of a Koebner phenomenon. This provides information about the origin of the palmar and plantar lesions observed with sorafenib.Keywords
This publication has 17 references indexed in Scilit:
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBritish Journal of Dermatology, 2009
- Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor TherapyClinical Cancer Research, 2009
- Dermatologic symptoms associated with the multikinase inhibitor sorafenibJournal of the American Academy of Dermatology, 2009
- Blackberry-induced hand-foot skin reaction to sunitinibInvestigational New Drugs, 2008
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinibAnnals of Oncology, 2008
- Sorafenib-Induced Eruptive Melanocytic LesionsArchives of Dermatology, 2008
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l’EGFAnnales de Dermatologie et de Vénéréologie, 2008
- Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapyBritish Journal of Dermatology, 2007
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005